Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Healthcare Disparities | 4 | 2021 | 178 | 0.920 |
Why?
|
| European Continental Ancestry Group | 8 | 2017 | 1163 | 0.800 |
Why?
|
| Colorectal Neoplasms | 4 | 2017 | 222 | 0.760 |
Why?
|
| Adenocarcinoma | 10 | 2016 | 300 | 0.750 |
Why?
|
| African Americans | 8 | 2017 | 1425 | 0.670 |
Why?
|
| Pancreatic Neoplasms | 7 | 2016 | 129 | 0.620 |
Why?
|
| Colonoscopy | 1 | 2017 | 45 | 0.520 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 476 | 0.500 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 471 | 0.500 |
Why?
|
| Transsexualism | 1 | 2016 | 4 | 0.490 |
Why?
|
| Minority Health | 1 | 2016 | 9 | 0.490 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 100 | 0.480 |
Why?
|
| Health Status Disparities | 2 | 2021 | 134 | 0.480 |
Why?
|
| Minority Groups | 1 | 2016 | 87 | 0.460 |
Why?
|
| Lung Neoplasms | 3 | 2017 | 429 | 0.440 |
Why?
|
| Rural Health | 1 | 2014 | 44 | 0.430 |
Why?
|
| Biomedical Research | 1 | 2016 | 172 | 0.420 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 166 | 0.420 |
Why?
|
| Common Bile Duct Neoplasms | 4 | 2016 | 6 | 0.410 |
Why?
|
| Ampulla of Vater | 4 | 2016 | 6 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 113 | 0.400 |
Why?
|
| Middle Aged | 30 | 2021 | 12203 | 0.380 |
Why?
|
| Oxidative Stress | 1 | 2014 | 243 | 0.380 |
Why?
|
| Aged | 25 | 2021 | 10637 | 0.360 |
Why?
|
| Gallbladder Neoplasms | 3 | 2021 | 34 | 0.350 |
Why?
|
| Prostatectomy | 5 | 2020 | 83 | 0.340 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2017 | 28 | 0.340 |
Why?
|
| Male | 30 | 2021 | 19754 | 0.340 |
Why?
|
| Appendiceal Neoplasms | 3 | 2017 | 98 | 0.340 |
Why?
|
| Humans | 37 | 2021 | 32967 | 0.330 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2016 | 18 | 0.310 |
Why?
|
| Drug Industry | 1 | 2009 | 17 | 0.310 |
Why?
|
| Female | 25 | 2021 | 20375 | 0.290 |
Why?
|
| Commerce | 1 | 2009 | 69 | 0.290 |
Why?
|
| Biological Products | 1 | 2009 | 77 | 0.280 |
Why?
|
| Bile Duct Neoplasms | 2 | 2018 | 32 | 0.270 |
Why?
|
| Blood Transfusion | 2 | 2017 | 76 | 0.260 |
Why?
|
| Mutation | 3 | 2017 | 499 | 0.240 |
Why?
|
| Adult | 18 | 2018 | 9586 | 0.240 |
Why?
|
| United States | 7 | 2021 | 4132 | 0.240 |
Why?
|
| Radiotherapy | 4 | 2020 | 82 | 0.240 |
Why?
|
| Carcinoid Tumor | 2 | 2016 | 13 | 0.240 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2015 | 6 | 0.240 |
Why?
|
| Dermatology | 2 | 2018 | 163 | 0.230 |
Why?
|
| Neuroendocrine Tumors | 2 | 2015 | 19 | 0.220 |
Why?
|
| DNA, Mitochondrial | 2 | 2015 | 34 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 193 | 0.220 |
Why?
|
| Adenoma | 2 | 2015 | 35 | 0.210 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 682 | 0.210 |
Why?
|
| Survival Rate | 9 | 2017 | 895 | 0.200 |
Why?
|
| SEER Program | 4 | 2017 | 33 | 0.200 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 4065 | 0.200 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 765 | 0.190 |
Why?
|
| Androgen Antagonists | 2 | 2020 | 19 | 0.190 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 2287 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2020 | 24 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2018 | 3708 | 0.170 |
Why?
|
| Cytodiagnosis | 2 | 2018 | 15 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2021 | 3460 | 0.170 |
Why?
|
| Bile Ducts | 2 | 2018 | 20 | 0.170 |
Why?
|
| Incidence | 3 | 2017 | 1246 | 0.160 |
Why?
|
| Prognosis | 7 | 2017 | 1547 | 0.150 |
Why?
|
| DNA, Neoplasm | 2 | 2017 | 54 | 0.140 |
Why?
|
| Registries | 2 | 2017 | 320 | 0.140 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 220 | 0.140 |
Why?
|
| Marital Status | 2 | 2016 | 23 | 0.140 |
Why?
|
| Risk Factors | 4 | 2021 | 4001 | 0.130 |
Why?
|
| Air Ambulances | 1 | 2017 | 10 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2017 | 14 | 0.130 |
Why?
|
| Pathology | 1 | 2017 | 16 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2017 | 31 | 0.130 |
Why?
|
| Esophagectomy | 1 | 2017 | 17 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 22 | 0.130 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 30 | 0.130 |
Why?
|
| Esophageal Neoplasms | 1 | 2017 | 39 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 576 | 0.130 |
Why?
|
| Resuscitation | 1 | 2017 | 67 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 6 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2017 | 107 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 35 | 0.120 |
Why?
|
| Epithelial Cells | 1 | 2017 | 129 | 0.120 |
Why?
|
| Critical Care | 1 | 2017 | 109 | 0.120 |
Why?
|
| Health Priorities | 1 | 2016 | 16 | 0.120 |
Why?
|
| Medicare | 1 | 2017 | 213 | 0.120 |
Why?
|
| Survivors | 1 | 2017 | 168 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2016 | 75 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 158 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2016 | 80 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 120 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2015 | 4 | 0.110 |
Why?
|
| Vitamins | 1 | 2015 | 73 | 0.110 |
Why?
|
| Electrons | 1 | 2015 | 12 | 0.110 |
Why?
|
| Mitotic Index | 1 | 2014 | 1 | 0.110 |
Why?
|
| Decision Making | 1 | 2017 | 203 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 192 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 29 | 0.110 |
Why?
|
| Georgia | 1 | 2014 | 14 | 0.110 |
Why?
|
| Isoprostanes | 1 | 2014 | 2 | 0.110 |
Why?
|
| Observer Variation | 3 | 2021 | 96 | 0.110 |
Why?
|
| beta Carotene | 1 | 2014 | 6 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2015 | 94 | 0.110 |
Why?
|
| Africa, Western | 1 | 2014 | 4 | 0.110 |
Why?
|
| Carotenoids | 1 | 2014 | 9 | 0.110 |
Why?
|
| Gene Dosage | 1 | 2014 | 35 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2015 | 114 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 77 | 0.110 |
Why?
|
| Age Factors | 5 | 2017 | 1202 | 0.110 |
Why?
|
| Vitamin D | 1 | 2015 | 189 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2015 | 187 | 0.110 |
Why?
|
| Social Class | 1 | 2014 | 93 | 0.100 |
Why?
|
| Age Distribution | 1 | 2014 | 201 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2020 | 2338 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 117 | 0.100 |
Why?
|
| Calcium | 1 | 2015 | 323 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 412 | 0.100 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2012 | 2 | 0.100 |
Why?
|
| Gallbladder | 1 | 2012 | 3 | 0.100 |
Why?
|
| Polyps | 1 | 2012 | 9 | 0.090 |
Why?
|
| Comorbidity | 1 | 2014 | 573 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 217 | 0.090 |
Why?
|
| Diet | 1 | 2014 | 393 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 497 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 770 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2010 | 15 | 0.080 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.080 |
Why?
|
| Mucins | 3 | 2016 | 17 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Neoplasms | 1 | 2017 | 762 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1581 | 0.080 |
Why?
|
| Drugs, Generic | 1 | 2009 | 15 | 0.080 |
Why?
|
| Lymphatic Metastasis | 3 | 2016 | 169 | 0.080 |
Why?
|
| Young Adult | 4 | 2018 | 2738 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 894 | 0.070 |
Why?
|
| Disease Progression | 3 | 2017 | 594 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2020 | 12 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 183 | 0.070 |
Why?
|
| Urinary Incontinence | 2 | 2020 | 48 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2017 | 1852 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 137 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 563 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 326 | 0.060 |
Why?
|
| Logistic Models | 2 | 2017 | 783 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 486 | 0.060 |
Why?
|
| Allelic Imbalance | 1 | 2004 | 6 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 14 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 2195 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 1469 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2004 | 384 | 0.040 |
Why?
|
| Chile | 1 | 2021 | 7 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2021 | 12 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 240 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 3643 | 0.040 |
Why?
|
| Pancreatic Ducts | 1 | 2018 | 6 | 0.040 |
Why?
|
| Appendectomy | 1 | 2017 | 19 | 0.030 |
Why?
|
| Colectomy | 1 | 2017 | 30 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 15 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 13 | 0.030 |
Why?
|
| Genes, erbB-1 | 1 | 2017 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 35 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2017 | 17 | 0.030 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 28 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2017 | 23 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 25 | 0.030 |
Why?
|
| Military Medicine | 1 | 2017 | 26 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 48 | 0.030 |
Why?
|
| Abbreviated Injury Scale | 1 | 2017 | 56 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 78 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 63 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2017 | 111 | 0.030 |
Why?
|
| Emotions | 1 | 2017 | 59 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2017 | 86 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1068 | 0.030 |
Why?
|
| Urination | 1 | 2016 | 16 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 84 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 29 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 292 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 41 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 98 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 145 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 467 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 319 | 0.030 |
Why?
|
| Anxiety | 1 | 2017 | 195 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2016 | 125 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2015 | 5 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2015 | 16 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 156 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 93 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 71 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 6 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2015 | 51 | 0.030 |
Why?
|
| Mycosis Fungoides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 97 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 290 | 0.030 |
Why?
|
| Base Sequence | 1 | 2015 | 249 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 316 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 356 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 780 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 543 | 0.030 |
Why?
|
| Rural Population | 1 | 2016 | 286 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 369 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 684 | 0.030 |
Why?
|
| Phenotype | 1 | 2015 | 644 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2014 | 225 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 531 | 0.020 |
Why?
|
| Keratin-7 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mucin-2 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Mucin-6 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Keratin-20 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 20 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 32 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 52 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2012 | 71 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 599 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 976 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 22 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 469 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2009 | 34 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 754 | 0.020 |
Why?
|
| Child | 1 | 2015 | 2478 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2004 | 7 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 199 | 0.010 |
Why?
|